PatientsVille.com Logo


Korlym Medical Research Studies

Up-to-date List of Korlym Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Korlym Medical Research Studies

Rank Status Study
1 Recruiting Mifepristone Treatment of Alcohol Use Disorder
Conditions: Alcohol Dependence;   Alcohol Use Disorders;   Alcohol Abuse;   Alcoholism
Interventions: Drug: Mifepristone 1200 mg daily;   Behavioral: Standardized behavioral therapy;   Drug: Mifepristone 600 mg daily;   Drug: Placebo
Outcome Measures: Drinking;   Craving
2 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Recommended phase II dose defined as the highest mifepristone dose in combination with enzalutamide such that < 33% experience dose-limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I);   PSA progression-free survival (PFS) defined as a PSA (confirmed 2 weeks later) that is >= 1.25 times (25% increase) the PSA at randomization (week 12) (Phase II);   Overall survival (Phase II);   Radiographic PFS (Phase II);   Pharmacokinetic (PK) parameters of enzalutamide and mifepristone;   AR expression within circulating tumor cells (CTCs);   GR expression within CTCs
3 Recruiting Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
Condition: Legally Induced Abortion Without Mention of Complication
Interventions: Other: Hygroscopic cervical dilators;   Drug: Misoprostol;   Drug: Intra-amniotic digoxin;   Drug: Mifepristone
Outcome Measures: Procedure Time;   Total Procedure Time;   Maximum Cervical Dilation;   Adverse Events;   Ease of Procedure by Blinded Surgeon;   Pain Perceived by Patient;   Overall patient experience
4 Not yet recruiting Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial
Conditions: Missed Abortion;   Pregnancy
Interventions: Drug: Mifepristone;   Drug: Misoprostol
Outcome Measures: Rate of successful evacuation of the uterus;   Rate of successful evacuation without any additional intervention;   Excessive bleeding or a complication for which a woman received treatment;   Induction expulsion interval after misoprostol administration;   Acceptability of assigned method to women
5 Unknown  Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks
Conditions: Induced Abortion;   Abortion Techniques;   Mifepristone;   Misoprostol
Interventions: Drug: Mifepristone;   Drug: Misoprostol
Outcome Measures: Initial cervical dilation at the time of surgical abortion;   Additional cervical dilation required to complete abortion procedure;   Time to conduct procedure;   Percentage of patients who report nausea, vomiting, diarrhea, and vaginal bleeding;   Preoperative, intraoperative, and postoperative pain score;   Surgeon's difficulty rating of procedure;   Complications of procedure
6 Recruiting Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Conditions: Breast Cancer;   Ovarian Epithelial Cancer Recurrent;   Sarcoma;   Non-small Cell Lung Cancer;   Carcinoma, Transitional Cell;   Prostate Cancer;   Prostatic Neoplasms
Intervention: Drug: Mifepristone and Eribulin in combination
Outcome Measure: Determine the MTD and recommended Phase 2 dose (RP2D) of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors.
7 Recruiting Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Condition: Mild Hypercortisolism
Intervention: Drug: Mifepristone
Outcome Measures: hyperglycemia;   Metabolic Syndrome;   Quality of Life
8 Recruiting Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
Condition: Stress Disorders, Post-Traumatic
Intervention: Drug: Mifepristone (600 mg/day) or placebo (sugar pill)
Outcome Measures: Presence or absence of a clinical response, defined as a 30% or greater reduction in total CAPS (past week symptom status);   Changes in CAPS (past week symptom status) score from baseline to weeks 1, 4, and 12 to capture time by treatment interaction, the proportion of clinical responders at 12 weeks for deciding sustainability, the time to addition of rescue medication to det
9 Unknown  Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh
Condition: Menstrual Regulation
Intervention: Drug: Mifepristone and misoprostol
Outcome Measure: successful menstrual regulation without the need for a surgical evacuation
10 Recruiting Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals
Condition: Depression
Intervention: Drug: 28 days treatment with Mifepristone.
Outcome Measures: Cognition;   Hamilton Score
11 Recruiting Mifepristone for the Prevention of Relapses of Alcohol Drinking
Condition: Alcohol Use Disorders (AUD)
Intervention: Drug: Mifepristone 600-mg/day for a week
Outcome Measures: Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Alcohol craving score on the Alcohol Craving Questionnaire;   Drinking consumption
12 Unknown  Developing Memory Reconsolidation Blockers as Novel Post-traumatic Stress Disorder (PTSD) Treatments
Condition: Post-traumatic Stress Disorder
Interventions: Drug: Mifepristone;   Drug: Cycloserine;   Drug: sugar pill
Outcome Measure: Psychophysiologic Responses during script-driven imagery of traumatic events
13 Recruiting Medication Enhanced Rapid Therapy
Condition: Anxiety Disorders
Intervention: Drug: d-cycloserine and mifepristone
Outcome Measures: Will measure medication tolerability and safety per participant report (i.e. few or no side effects severe enough to stop treatment);   Improvements in Anxiety as measured by several Self Report Assessments;   Level of Anxiety as measured by several Self Report Assessments
14 Recruiting A Randomized Clinical Trial of Mifepristone in PTSD
Condition: PTSD
Interventions: Drug: 600 mg/day Mifepristone;   Drug: Placebo
Outcome Measure: CAPS score
15 Recruiting Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan
Condition: Complete Abortion
Intervention: Drug: Mifepristone, misoprostol
Outcome Measures: Rate of successful abortion;   Satisfaction with method
16 Recruiting Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Interventions: Drug: Mifepristone;   Drug: Placebo
Outcome Measures: Resolution of Sub-retinal Fluid;   Change in sub-retinal fluid and/or intraretinal fluid;   Best Corrected Visual Acuity;   Change in macular thickness;   Change in foveal thickness;   Change in choroidal thickness;   Dye leakage in vasculature;   Change in OCT characteristics in the fellow eye;   Proportion of acute vs. chronic CSC patients;   Safety and Tolerability Characteristics
17 Recruiting BRCA1/2 and Effect of Mifepristone on the Breast
Condition: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA-1 and -2.
Intervention: Drug: Mifepristone
Outcome Measures: epithelial cell proliferation in breast tissue;   Vital signs and safety lab analysis;   Side effects and Adverse Events;   Endometrial effects;   Ovarian effects;   Breast symptom evaluation
18 Recruiting Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder
Condition: Posttraumatic Stress Disorder
Interventions: Drug: mifepristone;   Drug: placebo
Outcome Measures: Change from baseline on the total severity of the CAPS-2 and dichotomously defined clinical responder status.;   Change in cognitive functioning as measured by the MATRICS neuropsychological test battery and self-reported measures of depression and PTSD.
19 Recruiting Comparative Effectiveness of Pregnancy Failure Management Regimens
Condition: Spontaneous Abortion
Interventions: Drug: Misoprostol;   Drug: Mifepristone
Outcome Measure: Gestational sac expulsion with one treatment dose and no need for additional medical or surgical intervention.
20 Recruiting Mifepristone for Metabolic Syndrome
Conditions: Endocrine Disease;   Diabetes
Intervention: Drug: Mifepristone
Outcome Measures: To change in insulin sensitivity index based on the effect of insulin on glucose during frequently sampled IV glucose tolerance test (FSIVGTT);   Whole-body rate of regenerating cortisol response to mifepristone of glucose insulin sensitivity, free fatty acid clearance, cortisol metabolites, adrenal hormones.

These studies may lead to new treatments and are adding insight into Korlym etiology and treatment.

A major focus of Korlym research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Korlym